<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Pathol. Oncol. Res.</journal-id>
<journal-title-group>
<journal-title>Pathology &#x26; Oncology Research</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Pathol. Oncol. Res.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">1532-2807</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1612455</article-id>
<article-id pub-id-type="doi">10.3389/pore.2026.1612455</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Frequency and clinicopathological features of somatic neoplasms arising in ovarian mature teratomas: a single-center experience</article-title>
<alt-title alt-title-type="left-running-head">Y&#x131;ld&#x131;r&#x131;m et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/pore.2026.1612455">10.3389/pore.2026.1612455</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Y&#x131;ld&#x131;r&#x131;m</surname>
<given-names>&#x15e;enay</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/3417091"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal Analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal Analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>B&#xfc;lb&#xfc;l</surname>
<given-names>G&#xfc;l Alkan</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/3597908"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nergiz</surname>
<given-names>D&#xf6;nd&#xfc;</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1309981"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal Analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal Analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Y&#x131;ld&#x131;r&#x131;m</surname>
<given-names>H&#xfc;lya Tosun</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal Analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal Analysis</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>&#xd6;nder</surname>
<given-names>Arif Hakan</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data Curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data Curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>&#xdc;reyen</surname>
<given-names>I&#x15f;&#x131;n</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data Curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data Curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
</contrib>
</contrib-group>
<aff id="aff1">
<label>1</label>
<institution>Department of Pathology, Antalya Training and Research Hospital</institution>, <city>Antalya</city>, <country country="TR">T&#xfc;rkiye</country>
</aff>
<aff id="aff2">
<label>2</label>
<institution>Department of Perinatology, Antalya Training and Research Hospital</institution>, <city>Antalya</city>, <country country="TR">T&#xfc;rkiye</country>
</aff>
<aff id="aff3">
<label>3</label>
<institution>Department of Pathology, Health Sciences University, Antalya Training and Research Hospital</institution>, <city>Antalya</city>, <country country="TR">T&#xfc;rkiye</country>
</aff>
<aff id="aff4">
<label>4</label>
<institution>Department of Medical Oncology, Antalya Training and Research Hospital</institution>, <city>Antalya</city>, <country country="TR">T&#xfc;rkiye</country>
</aff>
<aff id="aff5">
<label>5</label>
<institution>Department of Gynecological Oncology, Health Sciences University, Antalya Training and Research Hospital</institution>, <city>Antalya</city>, <country country="TR">T&#xfc;rkiye</country>
</aff>
<author-notes>
<corresp id="c001">
<label>&#x2a;</label>Correspondence: &#x15e;enay Y&#x131;ld&#x131;r&#x131;m, <email xlink:href="mailto:dr_senayyildirim@hotmail.com">dr_senayyildirim@hotmail.com</email>
</corresp>
<fn fn-type="other" id="fn001">
<label>&#x2020;</label>
<p>ORCID: &#x15e;enay Y&#x131;ld&#x131;r&#x131;m, <uri xlink:href="https://orcid.org/0000-0002-1457-7957">orcid.org/0000-0002-1457-7957</uri>; G&#xfc;l Alkan B&#xfc;lb&#xfc;l, <uri xlink:href="https://orcid.org/0000-0002-6773-4573">orcid.org/0000-0002-6773-4573</uri>; D&#xf6;nd&#xfc; Nergiz, <uri xlink:href="https://orcid.org/0000-0002-8791-7713">orcid.org/0000-0002-8791-7713</uri>; H&#xfc;lya Tosun Y&#x131;ld&#x131;r&#x131;m, <uri xlink:href="https://orcid.org/0000-0002-4973-0982">orcid.org/0000-0002-4973-0982</uri>; Arif Hakan &#xd6;nder, <uri xlink:href="https://orcid.org/0000-0002-0121-5228">orcid.org/0000-0002-0121-5228</uri>; I&#x15f;&#x131;n &#xdc;reyen, <uri xlink:href="https://orcid.org/0000-0002-3491-4682">orcid.org/0000-0002-3491-4682</uri>
</p>
</fn>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-07-10">
<day>10</day>
<month>07</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>32</volume>
<elocation-id>1612455</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>04</month>
<year>2026</year>
</date>
<date date-type="rev-recd">
<day>28</day>
<month>06</month>
<year>2026</year>
</date>
<date date-type="accepted">
<day>03</day>
<month>07</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Y&#x131;ld&#x131;r&#x131;m, B&#xfc;lb&#xfc;l, Nergiz, Y&#x131;ld&#x131;r&#x131;m, &#xd6;nder and &#xdc;reyen.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Y&#x131;ld&#x131;r&#x131;m, B&#xfc;lb&#xfc;l, Nergiz, Y&#x131;ld&#x131;r&#x131;m, &#xd6;nder and &#xdc;reyen</copyright-holder>
<license>
<ali:license_ref start_date="2026-07-10">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Objective</title>
<p>Somatic neoplasms arising in mature teratomas (SN-MT) are rare clinical entities that pose significant diagnostic and therapeutic challenges. This study aims to determine the frequency of SN-MT and evaluate the clinicopathological characteristics that distinguish these cases from uncomplicated mature teratomas (MT).</p>
</sec>
<sec>
<title>Methods</title>
<p>We retrospectively reviewed 500 cases of presumed ovarian mature teratomas evaluated at a single center between 2006 and 2021. After strict exclusion criteria, 385 patients were included. All histopathological slides underwent systematic pathological re-evaluation by expert pathologists. Clinical, radiological, and laboratory data were compared between the MT and SN-MT groups.</p>
</sec>
<sec>
<title>Results</title>
<p>The overall incidence of somatic neoplasms (benign and malignant) was 3.1% (n &#x3d; 12), with a malignant transformation rate of 2.07% (n &#x3d; 8). The histological spectrum was highly heterogeneous and comprised both benign and malignant entities. Benign tumors identified in MTs included paraganglioma, choroid plexus papilloma, and adnexal tumor, whereas malignant tumors included squamous cell carcinoma (SCC), glioblastoma, anaplastic astrocytoma, adult-type granulosa cell tumor, and mixed carcinoma. The SN-MT group exhibited significantly larger mean tumor diameters compared to the MT group (9.45 &#xb1; 4.22&#xa0;cm vs. 6.67 &#xb1; 3.32 cm, p &#x3c; 0.05). On gross examination, mixed solid&#x2013;cystic architecture was a powerful predictor of neoplasia (83.3% in SN-MT vs. 22.3% in MT, p &#x3c; 0.0001). Preoperative serum tumor markers (CA 125, CA 19-9, and CEA) showed no significant discriminatory value. False-negative findings on intraoperative frozen section analysis may be attributable to the focal distribution of these lesions.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>SN-MT is a rare but histologically diverse condition. Large tumor size and the presence of solid components on macroscopic examination should raise suspicion of somatic transformation. Given the limitations of frozen section analysis and serum markers, rigorous macroscopic sampling and expert pathological examination remain the gold standard for diagnosis. While early-stage disease carries a favorable prognosis, the heterogeneity of subtypes necessitates individualized management.</p>
</sec>
</abstract>
<kwd-group>
<kwd>malignant transformation</kwd>
<kwd>mature teratoma</kwd>
<kwd>ovary</kwd>
<kwd>somatic neoplasm</kwd>
<kwd>squamous cell carcinoma</kwd>
<kwd>adult-type granulosa cell tumor</kwd>
<kwd>glioblastoma</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was not received for this work and/or its publication.</funding-statement>
</funding-group>
<counts>
<fig-count count="6"/>
<table-count count="4"/>
<equation-count count="0"/>
<ref-count count="31"/>
<page-count count="11"/>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p>Mature teratomas (MT) are common benign germ cell tumors composed of well-differentiated tissues from three embryonic layers [<xref ref-type="bibr" rid="B1">1</xref>]. Ovarian MTs, particularly the mature cystic subtype (MCT), represent 95% of all teratomas and 10%&#x2013;20% of all ovarian neoplasms [<xref ref-type="bibr" rid="B2">2</xref>]. While typically benign, these tumors can rarely give rise to secondary somatic malignancies, posing significant clinical and prognostic challenges.</p>
<p>Somatic neoplasms arising in mature teratomas (SN-MT), often termed &#x201c;somatic malignant transformation,&#x201d; occur in 1%&#x2013;2% of cases [<xref ref-type="bibr" rid="B3">3</xref>]. Despite their rarity, increased risk is associated with advanced patient age, larger tumor size, and prolonged duration of the tumor. While the majority of somatic neoplasms that develop from mature teratomas are malignant, benign or borderline neoplasms have also been documented on occasion. Squamous cell carcinoma (SCC) is the most frequently reported subtype. Other entities include adenocarcinoma, sarcomas (particularly rhabdomyosarcoma), neuroendocrine tumors, melanoma, and rare hematologic malignancies [<xref ref-type="bibr" rid="B4">4</xref>].</p>
<p>The pathogenesis of SN-MT remains unclear, with proposed mechanisms including chronic inflammation and genetic instability. Molecular studies suggest roles for TP53 and PIK3CA alterations, though it remains uncertain whether these events originate from benign tissue or secondary malignant clones [<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>]. Clinically, SN-MT typically presents with nonspecific symptoms like abdominal pain or pelvic masses. While serum markers like SCC antigen and CEA may be elevated in specific cases, they offer limited diagnostic utility [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>]. Consequently, preoperative differentiation remains difficult, necessitating histopathological confirmation.</p>
<p>Malignant transformation in mature teratomas is characterized by the presence of invasive malignancy within a background of benign teratomatous tissue [<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>]. Malignant areas often demonstrate stromal invasion, desmoplastic reactions, marked cytologic atypia, increased mitotic activity, and necrosis. Because these lesions are frequently focal and heterogeneously distributed, small malignant foci may be missed during routine sampling. Therefore, extensive and systematic gross sampling, particularly of the solid areas, mural thickening, necrosis, and hemorrhage, is essential. Immunohistochemistry is critical for distinguishing malignancies arising in mature teratomas from primary or metastatic ovarian malignancies [<xref ref-type="bibr" rid="B11">11</xref>&#x2013;<xref ref-type="bibr" rid="B13">13</xref>].</p>
<p>Prognosis depends on histologic subtype, stage, and surgical success, with radical surgery serving as the cornerstone of therapy [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>]. Adjuvant treatments should be individualized based on the somatic component rather than conventional germ cell regimens. Given that current evidence is largely limited to small series, the true frequency and prognostic determinants of SN-MT remain poorly defined [<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>]. This study aims to determine the frequency of SN-MT and compare clinicopathological features across various histologic subtypes.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and methods</title>
<sec id="s2-1">
<title>Study design and case selection</title>
<p>This retrospective study included cases evaluated in our pathology department between January 2006 and December 2021, with a diagnosis or presumptive diagnosis of mature teratoma. A total of 500 female patients were screened. Cases were excluded if (i) the final histopathologic diagnosis was immature teratoma; (ii) the diagnosis was not consistent with mature teratoma upon review; or (iii) the clinical, radiologic, or pathologic data were incomplete. After applying the exclusion criteria, 115 patients were excluded, and 385 women with mature teratomas were included in the final analysis (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Flow diagram illustrating patient selection and formation of the final study cohort.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="pore-32-1612455-g001.tif">
<alt-text content-type="machine-generated">Flowchart summarizing patient selection for a study on mature teratoma, showing 500 initially evaluated, 115 exclusions due to immature teratoma, inconsistent diagnosis, or incomplete data, and resulting in 385 included in final analysis.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s2-2">
<title>Data collection</title>
<p>Clinical, laboratory, and pathological data were retrospectively obtained from patient records and hospital information systems. Clinical variables included age, tumor location (right/left ovary), surgical procedures performed, and treatments received. Laboratory variables included preoperative serum CA 125, CA 19-9, and CEA levels when available.</p>
</sec>
<sec id="s2-3">
<title>Histopathological evaluation</title>
<p>Pathological variables assessed included tumor size, sectional characteristics (cystic, solid, or mixed cystic), and accompanying macroscopic findings. For histopathological examination, systematic sampling was performed, ensuring that at least one tissue section was obtained for every centimeter of the tumor&#x2019;s maximum diameter. Tissue samples were fixed in 10% neutral buffered formalin for 24&#x2013;48&#xa0;h, routinely processed, and embedded in paraffin blocks. Sections with a thickness of 3&#x2013;4&#xa0;&#x3bc;m were cut and stained with hematoxylin and eosin (H&#x26;E). To ensure diagnostic accuracy, all histopathological slides were re-evaluated by the authors based on current diagnostic criteria to confirm the final diagnosis.</p>
</sec>
<sec id="s2-4">
<title>Immunohistochemistry</title>
<p>In cases where the development of a secondary neoplasm within a mature teratoma was suspected, immunohistochemical (IHC) staining (P40, P63, GFAP, S100, Calretinin, Chromogranin, Synaptophysin, KI 67, etc.) was performed for definitive tumor typing. For IHC analysis, 3-4&#xa0;&#x3bc;m thick sections were taken from representative paraffin-embedded tumor blocks and placed on poly-L-lysine-coated slides. Immunohistochemical staining was performed using the Roche Ventana Benchmark Ultra system, following the manufacturer&#x2019;s instructions.</p>
</sec>
<sec id="s2-5">
<title>Statistical analysis</title>
<p>Descriptive statistics are presented as frequency and percentage for categorical variables and as mean &#xb1; standard deviation, median, minimum&#x2013;maximum, and 25th (Q1) and 75th (Q3) percentiles for continuous variables. For categorical comparisons, Pearson&#x2019;s chi-square test was used when &#x3c;20% of the expected cell counts were &#x3c;5; otherwise, Fisher&#x2019;s exact test was used. Normality was assessed using the Shapiro&#x2013;Wilk test. As the continuous variables did not follow a normal distribution, group comparisons were performed using the Mann&#x2013;Whitney U test. All analyses were conducted using IBM SPSS Statistics version 23.0, and statistical significance was set at p &#x3c; 0.05.</p>
</sec>
<sec id="s2-6">
<title>Ethics approval</title>
<p>This study was reviewed and approved by the ethics committee of Antalya Training and Research Hospital (approval number: 11/3, Date: 23.7.2020). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<p>A total of 385 women with histologically confirmed mature teratomas were included. The incidence of benign and malignant somatic neoplasms originating from mature teratomas was found to be 3.1% (n &#x3d; 12). The frequency of malignant transformation from mature teratomas was found to be 2.07% (n &#x3d; 8). The histological spectrum was heterogeneous, comprising both benign and malignant entities. Benign tumors identified in MTs included paraganglioma (16.6%), choroid plexus papilloma (8.3%), and adnexal tumor (8.3%), while malignant tumors included squamous cell carcinoma (SCC) (33.3%), glioblastoma (8.3%), anaplastic astrocytoma (8.3%), adult-type granulosa cell tumor (8.3%), and mixed carcinoma (8.3%).</p>
<p>Among the 373 MT cases (96.9%) without somatic neoplasia, the mean age was 37.75 &#xb1; 14.18 years (range, 13&#x2013;83 years). The tumors were located in the right (48.2%), left (45.6%), and bilateral (6.2%) ovaries. The mean tumor diameter was 6.67 &#xb1; 3.32&#xa0;cm (range, 1.5&#x2013;17). On gross examination, 77.7% were cystic, and 22.3% were solid&#x2013;cystic.</p>
<p>The mean age of the SN-MT group was 43.0 &#xb1; 18.27&#xa0;years (range, 20&#x2013;73&#xa0;years). Tumors were located in the right ovary in 75% of the cases and in the left ovary in 25% of the cases. It was observed that none of the SN-MT cases was bilateral. The mean tumor diameter was 9.45 &#xb1; 4.22&#xa0;cm (range, 3.5&#x2013;15). Grossly, 83.3% of the SN-MT cases showed mixed solid&#x2013;cystic components, whereas only two cases (16.7%) were purely cystic (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Comparison of age and tumor size between MT and SN-MT groups.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Diagnostic group</th>
<th align="center">MT</th>
<th align="center">MT</th>
<th align="center">SN-MT</th>
<th align="center">SN-MT</th>
<th align="center">
<italic>p</italic>
</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">Diagnostic group</td>
<td align="center">Mean &#xb1; SD (Min&#x2013;Max)</td>
<td align="center">Median (Q1&#x2013;Q3)</td>
<td align="center">Mean &#xb1; SD (Min&#x2013;Max)</td>
<td align="left">Median (Q1&#x2013;Q3)</td>
<td align="left">&#x200b;</td>
</tr>
<tr>
<td align="center">Age (years)</td>
<td align="center">37.76 &#xb1; 14.19 (13&#x2013;82)</td>
<td align="center">36 (27&#x2013;47)</td>
<td align="center">43.00 &#xb1; 18.28 (20&#x2013;73)</td>
<td align="center">37 (28.5&#x2013;60.5)</td>
<td align="left">0.390</td>
</tr>
<tr>
<td align="center">Left-sided tumor size (cm)</td>
<td align="center">6.76 &#xb1; 3.78 (0.8&#x2013;35)</td>
<td align="center">6 (4.5&#x2013;8)</td>
<td align="center">14.0 &#xb1; 1.0 (13&#x2013;15)</td>
<td align="center">14 (13&#x2013;15)</td>
<td align="left">0.006</td>
</tr>
<tr>
<td align="center">Right-sided tumor size (cm)</td>
<td align="center">6.36 &#xb1; 2.74 (0.1&#x2013;20)</td>
<td align="center">6 (4.5&#x2013;8)</td>
<td align="center">7.94 &#xb1; 3.74 (3.5&#x2013;14)</td>
<td align="center">7 (5&#x2013;10)</td>
<td align="left">0.243</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>MT: Mature teratoma SN-MT: somatic neoplasms arising in mature teratomas.</p>
</fn>
<fn>
<p>The Mann Whitney U test was used. Q1: 25. Percentile and Q3:75. Percentile.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>There was no significant difference between the MT and SN-MT groups in terms of age (p &#x3d; 0.390) or the proportion of patients aged &#x3c;45 years versus &#x2265;45 years (p &#x3d; 0.333). Tumor laterality (right/left/bilateral) did not differ significantly between the groups (p &#x3d; 0.170). When tumor size was analyzed by laterality, left-sided tumors differed significantly between the groups (p &#x3d; 0.006), with larger tumors in the SN-MT group; right-sided tumors did not differ significantly (p &#x3d; 0.243). Gross cut-surface characteristics differed markedly between the groups (p &#x3c; 0.0001). MTs were predominantly cystic, whereas SN-MTs were predominantly mixed solid&#x2013;cystic (<xref ref-type="table" rid="T2">Table 2</xref>).</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Comparison of clinical and gross features between MT and SN-MT groups.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Variable</th>
<th align="center">MT n (%)</th>
<th align="center">SN-MT n (%)</th>
<th align="center">Total n (%)</th>
<th align="center">
<italic>p</italic>
</th>
<th align="center">Odds ratio&#x2a; (95% CI)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<th colspan="6" align="left">Age (years)</th>
</tr>
<tr>
<td align="center">&#x3c;45</td>
<td align="center">267 (71.6)</td>
<td align="center">7 (58.3)</td>
<td align="center">274 (71.1)</td>
<td align="left">0.333<sup>2</sup>
</td>
<td align="center">1.845 (0.573&#x2013;5.943)</td>
</tr>
<tr>
<td align="center">&#x2265;45</td>
<td align="center">106 (28.4)</td>
<td align="center">5 (41.7)</td>
<td align="center">111 (28.9)</td>
<td align="left">&#x200b;</td>
<td align="left">&#x200b;</td>
</tr>
<tr>
<td align="center">Total</td>
<td align="center">373 (100)</td>
<td align="center">12 (100)</td>
<td align="center">385 (100)</td>
<td align="left">&#x200b;</td>
<td align="left">&#x200b;</td>
</tr>
<tr>
<th colspan="6" align="left">Gross cut-surface</th>
</tr>
<tr>
<td align="center">Cystic</td>
<td align="center">290 (77.7)</td>
<td align="center">2 (16.7)</td>
<td align="center">292 (75.5)</td>
<td align="left">&#x3c;0.0001<sup>2</sup>
</td>
<td align="center">17.169 (3.689&#x2013;79.904)</td>
</tr>
<tr>
<td align="center">Solid &#x2b; cystic</td>
<td align="center">83 (22.3)</td>
<td align="center">10 (83.3)</td>
<td align="center">93 (24.5)</td>
<td align="left">&#x200b;</td>
<td align="left">&#x200b;</td>
</tr>
<tr>
<td align="center">Total</td>
<td align="center">373 (100)</td>
<td align="center">12 (100)</td>
<td align="center">385 (100)</td>
<td align="left">&#x200b;</td>
<td align="left">&#x200b;</td>
</tr>
<tr>
<th colspan="6" align="left">Tumor laterality</th>
</tr>
<tr>
<td align="center">Right</td>
<td align="center">180 (48.2)</td>
<td align="center">9 (75.0)</td>
<td align="center">189 (49.1)</td>
<td align="left">0.170<xref ref-type="table-fn" rid="Tfn1">
<sup>1</sup>
</xref>
</td>
<td align="left">&#x200b;</td>
</tr>
<tr>
<td align="center">Left</td>
<td align="center">170 (45.6)</td>
<td align="center">3 (25.0)</td>
<td align="center">173 (45.0)</td>
<td align="left">&#x200b;</td>
<td align="left">&#x200b;</td>
</tr>
<tr>
<td align="center">Bilateral</td>
<td align="center">23 (6.2)</td>
<td align="center">0 (0)</td>
<td align="center">23 (5.9)</td>
<td align="left">&#x200b;</td>
<td align="left">&#x200b;</td>
</tr>
<tr>
<td align="center">Total</td>
<td align="center">373 (100)</td>
<td align="center">12 (100)</td>
<td align="center">385 (100)</td>
<td align="left">&#x200b;</td>
<td align="left">&#x200b;</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="Tfn1">
<label>1</label>
<p>Pearson chi-square test and2: Fisher&#x2019;s Exact test were used. &#x2a;: Odds ratio is obtained from 2x2 tables.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Preoperative serum CA 125 was available for 274 patients, CA 19-9 for 251, and CEA for 191 patients, respectively. No significant differences were observed between the MT and SN-MT groups for CA 125, CA 19-9, or CEA (all p &#x3d; 0.99). The marker levels are summarized in <xref ref-type="table" rid="T3">Table 3</xref>.</p>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Comparison of serum tumor marker levels between MT and SN-MT groups.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Variable</th>
<th align="center">MT n (%)</th>
<th align="center">SN-MT n (%)</th>
<th align="center">Total n (%)</th>
<th align="center">
<italic>p</italic>
</th>
<th align="center">Odds ratio (95% CI)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<th colspan="6" align="left">CA 125 (U/mL)</th>
</tr>
<tr>
<td align="center">&#x3c;35</td>
<td align="center">233 (87.9)</td>
<td align="center">8 (88.9)</td>
<td align="center">241 (88.0)</td>
<td align="center">0.99</td>
<td align="center">0.91 (0.11&#x2013;7.518)</td>
</tr>
<tr>
<td align="center">&#x2265;35</td>
<td align="center">32 (12.1)</td>
<td align="center">1 (11.1)</td>
<td align="center">33 (12.0)</td>
<td align="left">&#x200b;</td>
<td align="left">&#x200b;</td>
</tr>
<tr>
<td align="center">Total</td>
<td align="center">265 (100)</td>
<td align="center">9 (100)</td>
<td align="center">274 (100)</td>
<td align="left">&#x200b;</td>
<td align="left">&#x200b;</td>
</tr>
<tr>
<th colspan="6" align="left">CA 19-9 (U/mL)</th>
</tr>
<tr>
<td align="center">&#x3c;37</td>
<td align="center">182 (74.9)</td>
<td align="center">6 (75.0)</td>
<td align="center">188 (74.9)</td>
<td align="center">0.99</td>
<td align="center">0.995 (0.196&#x2013;5.058)</td>
</tr>
<tr>
<td align="center">&#x2265;37</td>
<td align="center">61 (25.1)</td>
<td align="center">2 (25.0)</td>
<td align="center">63 (25.1)</td>
<td align="left">&#x200b;</td>
<td align="left">&#x200b;</td>
</tr>
<tr>
<td align="center">Total</td>
<td align="center">243 (100)</td>
<td align="center">8 (100)</td>
<td align="center">251 (100)</td>
<td align="left">&#x200b;</td>
<td align="left">&#x200b;</td>
</tr>
<tr>
<th colspan="6" align="left">CEA (ng/mL)</th>
</tr>
<tr>
<td align="center">&#x3c;2.5</td>
<td align="center">156 (85.2)</td>
<td align="center">7 (87.5)</td>
<td align="center">163 (85.3)</td>
<td align="center">0.99</td>
<td align="center">0.825 (0.098&#x2013;6.979)</td>
</tr>
<tr>
<td align="center">&#x2265;2.5</td>
<td align="center">27 (14.8)</td>
<td align="center">1 (12.5)</td>
<td align="center">28 (14.7)</td>
<td align="left">&#x200b;</td>
<td align="left">&#x200b;</td>
</tr>
<tr>
<td align="center">Total</td>
<td align="center">183 (100)</td>
<td align="center">8 (100)</td>
<td align="center">191 (100)</td>
<td align="left">&#x200b;</td>
<td align="left">&#x200b;</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Intraoperative frozen section evaluation was performed in 7/12 SN-MT cases (58.3%). Frozen sections were reported as benign in 4 cases and malignant in 3 cases. Among those reported as malignant, the final diagnoses included SCC (n &#x3d; 2) and mixed carcinoma (n &#x3d; 1). Among the frozen section&#x2013;benign cases, final pathology revealed glioblastoma, anaplastic astrocytoma, and SCC, indicating false-negative frozen section results. In five SN-MT cases where intraoperative frozen sections were not performed, microscopic evaluation of permanent sections revealed the development of choroid plexus papilloma, paraganglioma, skin adnexal tumor, and adult-type granulosa cell tumor. Intraoperative frozen section results, individual surgical and medical treatment plans for 12 SN-MT patients are reported in <xref ref-type="table" rid="T4">Table 4</xref>.</p>
<table-wrap id="T4" position="float">
<label>TABLE 4</label>
<caption>
<p>Presentation of somatic neoplasms arising in mature teratomas.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Case</th>
<th align="center">Age</th>
<th align="left">Type of procedure</th>
<th align="center">Result of frozen</th>
<th align="left">Immunohistochemistry</th>
<th align="left">Diagnosis</th>
<th align="center">Complementary surgery</th>
<th align="left">Stage</th>
<th align="center">Chemotherapy status</th>
<th align="left">Follow-up (months)</th>
<th align="left">Status</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">1</td>
<td align="left">60</td>
<td align="center">TAH &#x2b; BSO &#x2b; bilateral pelvic lymphadenectomy&#x2b;<break/>Omentectomy</td>
<td align="center">Malign</td>
<td align="center">P63 (&#x2b;)<break/>K&#x130; 67:%60</td>
<td align="center">SCC</td>
<td align="left">Not performed</td>
<td align="center">IC</td>
<td align="left">Not received</td>
<td align="left">108</td>
<td align="left">Deceased</td>
</tr>
<tr>
<td align="left">2</td>
<td align="left">33</td>
<td align="center">Bilateral cystectomy</td>
<td align="center">Benign</td>
<td align="center">P63 (&#x2b;)<break/>K&#x130; 67:%80</td>
<td align="center">SCC</td>
<td align="left">Unilateral salpingo-oophorectomy &#x2b; omentectomy &#x2b; Paraortic and bilateral pelvic lymphadenectomy</td>
<td align="center">IA</td>
<td align="left">Not received</td>
<td align="left">50</td>
<td align="left">Alive</td>
</tr>
<tr>
<td align="left">3</td>
<td align="left">73</td>
<td align="center">TAH &#x2b; BSO &#x2b; Paraortic and bilateral pelvic lymphadenectomy&#x2b;<break/>Omentectomy</td>
<td align="center">Malign</td>
<td align="center">P63 (&#x2b;)</td>
<td align="center">SCC</td>
<td align="left">Not performed</td>
<td align="center">IA</td>
<td align="left">Not received</td>
<td align="left">77</td>
<td align="left">Deceased</td>
</tr>
<tr>
<td align="left">4</td>
<td align="left">39</td>
<td align="center">TAH &#x2b; BSO &#x2b; Paraortic and bilateral pelvic lymphadenectomy &#x2b; Omentectomy</td>
<td align="center">Not performed</td>
<td align="center">P63 (&#x2b;)<break/>K&#x130;67:%70</td>
<td align="center">SCC</td>
<td align="left">Not performed</td>
<td align="center">IIIB</td>
<td align="left">1st line: Carboplatin &#x2b; Paclitaxel<break/>2nd line: Oxaliplatin &#x2b; Gemcitabin</td>
<td align="left">132</td>
<td align="left">Deceased</td>
</tr>
<tr>
<td align="left">5</td>
<td align="left">61</td>
<td align="center">TAH &#x2b; BSO &#x2b; Paraortic and bilateral pelvic lymphadenectomy&#x2b;<break/>Omentectomy</td>
<td align="center">Malign</td>
<td align="center">SCC: P40 (&#x2b;)<break/>
<styled-content style="color:#212121">Mucinous adenocarcinoma: CK20(&#x2b;) MUC1(&#x2b;) MUC2(&#x2b;)</styled-content>
<break/>High-grade adenocarcinoma: p53 overexpression</td>
<td align="center">Mixed carcinoma</td>
<td align="left">Not performed</td>
<td align="center">IIIA2</td>
<td align="left">VAC-IE (Vincristine, Adriamycin (Doxorubicin) and Cyclophosphamide (VAC) &#x2b; Ifosfamide and etoposide</td>
<td align="left">67</td>
<td align="left">Deceased</td>
</tr>
<tr>
<td align="left">6</td>
<td align="left">20</td>
<td align="center">Left ovarian cystectomy</td>
<td align="center">Benign</td>
<td align="center">GFAP (&#x2b;)<break/>ATRX: Retained<break/>IDH-1: Wild type<break/>K&#x130;67:%30</td>
<td align="center">Glioblastoma</td>
<td align="left">Left USO &#x2b; omentectomy</td>
<td align="center">IIIA1</td>
<td align="left">BEP (bleomycin &#x2b; etoposide &#x2b; Cisplatin)</td>
<td align="left">46</td>
<td align="left">Alive</td>
</tr>
<tr>
<td align="left">7</td>
<td align="left">22</td>
<td align="center">Left ovarian cystectomy</td>
<td align="center">Benign</td>
<td align="center">GFAP (&#x2b;)<break/>ATRX: Nuclear expression lost<break/>IDH-1: Mutant<break/>K&#x130;67:%5</td>
<td align="center">Anaplastic astrocytoma</td>
<td align="left">Left USO &#x2b; omentectomy &#x2b; Paraortic and bilateral pelvic lymphadenectomy</td>
<td align="center">IA</td>
<td align="left">BEP (bleomycin &#x2b; etoposide &#x2b; Cisplatin)</td>
<td align="left">79</td>
<td align="left">Alive</td>
</tr>
<tr>
<td align="left">8</td>
<td align="left">50</td>
<td align="center">Right ovarian cystectomy</td>
<td align="center">Not performed</td>
<td align="center">&#x130;nhibin (&#x2b;) Calretinin (&#x2b;)</td>
<td align="center">Adult type granulosa cell tumor</td>
<td align="left">TAH &#x2b; BSO</td>
<td align="center">IA</td>
<td align="left">Not received</td>
<td align="left">126</td>
<td align="left">Alive</td>
</tr>
<tr>
<td align="left">9</td>
<td align="left">35</td>
<td align="center">Right ovarian cystectomy</td>
<td align="center">Not performed</td>
<td align="center">S100 (&#x2b;) GFAP (&#x2b;) K&#x130;67:%1</td>
<td align="center">Choroid plexus papilloma</td>
<td align="left">Not performed</td>
<td align="left">&#x200b;</td>
<td align="left">Not received</td>
<td align="left">107</td>
<td align="left">Alive</td>
</tr>
<tr>
<td align="left">10</td>
<td align="left">31</td>
<td align="center">Right ovarian cystectomy &#x2b; appendectomy</td>
<td align="center">Not performed</td>
<td align="center">Chromogranin (&#x2b;)<break/>Synaptophysin (&#x2b;)<break/>CD56 (&#x2b;) K&#x130;67:%2</td>
<td align="center">Paraganglioma</td>
<td align="left">Not performed</td>
<td align="left">&#x200b;</td>
<td align="left">Not received</td>
<td align="left">50</td>
<td align="left">Alive</td>
</tr>
<tr>
<td align="left">11</td>
<td align="left">26</td>
<td align="center">Bilateral cystectomy</td>
<td align="center">Not performed</td>
<td align="center">Chromogranin (&#x2b;)<break/>Synaptophysin (&#x2b;)<break/>CD56 (&#x2b;) K&#x130;67:%1</td>
<td align="center">Paraganglioma</td>
<td align="left">Not performed</td>
<td align="left">&#x200b;</td>
<td align="left">Not received</td>
<td align="left">55</td>
<td align="left">Alive</td>
</tr>
<tr>
<td align="left">12</td>
<td align="left">66</td>
<td align="center">TAH &#x2b; BSO</td>
<td align="center">Benign</td>
<td align="center">CK7(&#x2b;)ER (&#x2b;) PR (&#x2b;)</td>
<td align="center">Benign skin appendage tumor</td>
<td align="left">Not performed</td>
<td align="left">&#x200b;</td>
<td align="left">Not received</td>
<td align="left">108</td>
<td align="left">Alive</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>TAH &#x2b; BSO: Transabdominal hysterectomy &#x2b; Bilateral salpingo-oophorectomyUSO: Unilateral salpingo-oophorectomySCC: squamous cell carcinoma.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Among the benign neoplasms arising within mature teratomas, paraganglioma was characterized by the classic &#x201c;Zellballen&#x201d; nesting pattern of tumor cells separated by a delicate fibrovascular stroma (<xref ref-type="fig" rid="F2">Figure 2A</xref>); immunohistochemically, these cells demonstrated moderate cytoplasmic synaptophysin expression (<xref ref-type="fig" rid="F2">Figure 2B</xref>). The choroid plexus papilloma cases exhibited a complex papillary architecture lined by uniform epithelial cells (<xref ref-type="fig" rid="F2">Figure 2C</xref>), which showed strong S100 protein positivity along the epithelial lining (<xref ref-type="fig" rid="F2">Figure 2D</xref>). Additionally, adnexal skin appendage tumors were identified by their well-differentiated follicular or sebaceous structures closely associated with the ectodermal components of the teratoma.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Benign neoplasms arising in mature teratomas <bold>(A)</bold> Paraganglioma with characteristic &#x201c;Zellballen&#x201d; pattern (H&#x26;E, X100). <bold>(B)</bold> Moderate cytoplasmic synaptophysin expression in paraganglioma cells (Synaptophysin, X200). <bold>(C)</bold> Choroid plexus papilloma with complex papillary architecture (H&#x26;E, X200). <bold>(D)</bold> S100 protein expression in the epithelial lining of choroid plexus papilloma (S100, X200).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="pore-32-1612455-g002.tif">
<alt-text content-type="machine-generated">Panel A shows a histology slide stained with hematoxylin and eosin, highlighting clustered glandular structures. Panel B displays an immunohistochemistry image with pale brown cell membrane staining in similar glandular areas. Panel C presents another hematoxylin and eosin&#x2013;stained section, this time with more irregular and crowded glandular or tubular structures. Panel D shows immunohistochemistry with strong, widespread brown cytoplasmic staining in tumor cells, outlining glandular architecture.</alt-text>
</graphic>
</fig>
<p>Within the malignant category, the tumors followed diverse lineages. SCC displayed sheets and nests of atypical squamous cells infiltrating the stroma, prominent keratin pearl formation, and extensive intercellular bridges, alongside diffuse nuclear p63 positivity. Adult-type granulosa cell tumors showed prominent trabecular, insular, and microfollicular growth patterns (<xref ref-type="fig" rid="F3">Figure 3A</xref>), the latter containing numerous pathognomonic Call-Exner bodies; the neoplastic cells presented cuboidal-to-polygonal morphology with scant cytoplasm and characteristic pale, angulated, and grooved nuclei (<xref ref-type="fig" rid="F3">Figure 3B</xref>), accompanied by diffuse cytoplasmic positivity for inhibin (<xref ref-type="fig" rid="F3">Figure 3C</xref>) and calretinin.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Adult-type granulosa cell tumor arising within a mature teratoma. <bold>(A)</bold> The tumor exhibits granulosa cells arranged in trabecular and insular patterns, separated by fibromatous stroma (H&#x26;E, X100). <bold>(B)</bold> Microfollicular pattern with numerous Call-Exner bodies. The neoplastic cells are cuboidal-to-polygonal with scant cytoplasm and pale, uniform, angulated, and grooved (coffee-bean) nuclei (H&#x26;E, X400). <bold>(C)</bold> Diffuse cytoplasmic positivity for inhibin within the tumor cells (Inhibin, X100).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="pore-32-1612455-g003.tif">
<alt-text content-type="machine-generated">Panel A shows a histology section stained with hematoxylin and eosin, depicting dense clusters of cells within fibrous stroma. Panel B presents a higher magnification of cells with prominent purple nuclei and scattered pinkish extracellular material. Panel C displays an immunohistochemistry stain highlighting numerous brown-stained cells separated by blue fibrous tissue.</alt-text>
</graphic>
</fig>
<p>Among the neuroepithelial malignancies, glioblastoma displayed high-grade features, including markedly increased cellularity, prominent nuclear atypia, frequent atypical mitoses, and areas of necrosis with pseudopalisading (<xref ref-type="fig" rid="F4">Figures 4A,B</xref>) Immunohistochemically, the tumor cells showed diffuse GFAP positivity (<xref ref-type="fig" rid="F4">Figure 4C</xref>), retained nuclear ATRX expression (<xref ref-type="fig" rid="F4">Figure 4D</xref>), strong nuclear p53 overexpression (<xref ref-type="fig" rid="F4">Figure 4E</xref>), and a remarkably high Ki-67 proliferation index (<xref ref-type="fig" rid="F4">Figure 4F</xref>). In contrast, anaplastic astrocytoma presented as a glial proliferation adjacent to mature teratoma epithelia, exhibiting moderate pleomorphism without necrosis or prominent proliferative activity (<xref ref-type="fig" rid="F5">Figures 5A,B</xref>). Structurally, these cells revealed diffuse GFAP positivity (<xref ref-type="fig" rid="F5">Figure 5C</xref>), loss of nuclear ATRX (<xref ref-type="fig" rid="F5">Figure 5D</xref>), strong mutant IDH-1 (IDH1-R132H) immunoreactivity (<xref ref-type="fig" rid="F5">Figure 5E</xref>), and a low Ki-67 index (5%) (<xref ref-type="fig" rid="F5">Figure 5F</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Glioblastoma arising within a mature teratoma. <bold>(A)</bold> The tumor exhibits markedly increased cellularity, prominent nuclear atypia, and areas of necrosis (H&#x26;E, X100). <bold>(B)</bold> Pseudopalisading necrosis with neoplastic cells surrounding a central necrotic zone and frequent atypical mitotic figures (H&#x26;E, X200). <bold>(C)</bold> Diffuse GFAP positivity in tumor cells (X200). <bold>(D)</bold> Retained nuclear ATRX expression within the neoplastic cells (X100). <bold>(E)</bold> Diffuse and strong nuclear p53 overexpression in tumor cells (X100). <bold>(F)</bold> High Ki-67 proliferation index within the tumor cells (X100).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="pore-32-1612455-g004.tif">
<alt-text content-type="machine-generated">Panel A presents a histopathology slide with dense pink and purple staining indicating high cellularity. Panel B shows a similar cellular pattern with intense pink staining. Panel C displays immunohistochemistry with widespread brown staining indicating positive marker expression. Panel D features diffuse brown-stained nuclei scattered throughout a light background, characteristic of positive nuclear marker staining. Panel E and Panel F both depict numerous brown-stained nuclei on a pale blue background, with cellular density and staining distribution comparable across both slides.</alt-text>
</graphic>
</fig>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Anaplastic astrocytoma arising within a mature teratoma. <bold>(A)</bold> Glial cell proliferation adjacent to the epithelial components of the mature teratoma (H&#x26;E, X40). <bold>(B)</bold> Tumor cells demonstrating moderate pleomorphism, in the absence of necrosis and marked proliferative activity (H&#x26;E, X200). <bold>(C)</bold> Diffuse GFAP positivity in tumor cells (X100). <bold>(D)</bold> Loss of nuclear ATRX expression in neoplastic cells (X200). <bold>(E)</bold> Strong immunoreactivity for mutant IDH-1 (IDH1-R132H) within tumor cells (X200). <bold>(F)</bold> Low Ki-67 proliferation index, quantified at approximately 5% (X200).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="pore-32-1612455-g005.tif">
<alt-text content-type="machine-generated">Panel A shows a low-magnification histology slide with a well-circumscribed tumor, panel B presents a higher magnification view of tumor cells, and panel C highlights immunohistochemical staining with widespread brown coloration. Panel D demonstrates weak immunoreactivity for a nuclear marker, panel E shows strong, diffuse brown staining for a cytoplasmic marker, and panel F features scattered positive nuclei for a different immunohistochemical marker.</alt-text>
</graphic>
</fig>
<p>The mixed carcinoma case comprised three distinct malignant components. The first component consisted of infiltrative nests of atypical keratinized and non-keratinized squamous cells showing p40 positivity (<xref ref-type="fig" rid="F6">Figure 6A</xref>). Adjacent to these areas, a high-grade adenocarcinoma component was identified in a necrotic background, characterized by pleomorphic cells with papillary architecture and p53 overexpression (<xref ref-type="fig" rid="F6">Figure 6B</xref>). The intimate juxtaposition and transition between the squamous cell carcinoma and high-grade adenocarcinoma components were clearly demonstrated (<xref ref-type="fig" rid="F6">Figure 6C</xref>). Finally, a small focus of mucinous adenocarcinoma was present, composed of pleomorphic cells with prominent nucleoli and abundant vacuolated cytoplasm, showing positivity for MUC1 and MUC2 immunostains (<xref ref-type="fig" rid="F6">Figure 6D</xref>). Notably, p53 demonstrated a wild-type expression pattern in both the squamous and mucinous adenocarcinoma. components. In the MT group, cystectomy was performed in 60.5% of the patients, USO in 20%, and TAH &#x2b; BSO in 19.5%. The SN-MT group underwent Total Abdominal Hysterectomy &#x2b; Bilateral Salpingo-Oophorectomy (TAH &#x2b; BSO) in 41.7% of the patients, unilateral salpingo-oophorectomy (USO) in 41.7%, and cystectomy in 16.6%. Of the eight cases exhibiting malignant transformation, four were diagnosed following TAH &#x2b; BSO, while the remaining four were diagnosed via unilateral/bilateral ovarian cystectomy. According to the 8th edition of the American Joint Committee on Cancer (AJCC) staging system, the distribution was as follows: Stage I (n &#x3d; 5) and Stage III (n &#x3d; 3). The clinicopathological and surgical characteristics of the SN-MT cases are detailed in <xref ref-type="table" rid="T4">Table 4</xref>.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Histopathological components of the mixed carcinoma arising in a mature cystic teratoma. <bold>(A)</bold> Areas of squamous cell carcinoma (SCC) showing invasive nests of malignant epithelial cells (H&#x26;E, X100). <bold>(B)</bold> Foci of high-grade adenocarcinoma characterized by complex architectural patterns within extensive areas of necrosis (H&#x26;E, X100). <bold>(C)</bold> The transition zone demonstrating the junction between the SCC and high-grade adenocarcinoma components (H&#x26;E, X100). <bold>(D)</bold> Mucinous adenocarcinoma component composed of cells with large vacuolated cytoplasm, exhibiting a pattern of single-cell infiltration within the stroma (H&#x26;E, X100).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="pore-32-1612455-g006.tif">
<alt-text content-type="machine-generated">Panel A shows a histological section with a fibrous stroma and scattered cellular areas stained in shades of pink and purple. Panel B displays densely packed dark-staining cells with glandular-like structures throughout the field. Panel C presents a transition between two distinct tissue types: a cellular, purple-stained area on the left and a more fibrous, pink-stained region on the right. Panel D features a rounded tissue section with glandular formations and fibrous stroma distributed throughout.</alt-text>
</graphic>
</fig>
<p>At diagnosis, para-aortic lymph node metastasis was detected only in the mixed carcinoma case; at 31 months, the patient developed right adrenal metastasis. The adrenal metastasis was confirmed to be of ovarian origin, as whole-body PET-CT imaging demonstrated no other primary tumour focus, thereby excluding a synchronous or metachronous secondary malignancy. The SN-MT group was followed for a mean of 80.3 &#xb1; 6.13 months (range, 50-132).</p>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>In the present study, we evaluated the frequency and clinicopathological characteristics of somatic neoplasms arising in mature teratomas in a large cohort over an extended study period. The incidence of malignant transformation was 2.07%, which falls within the reported range of 0.17%&#x2013;5.5% in the literature, although it is higher than the 0.54% rate reported by Neville et al. [<xref ref-type="bibr" rid="B18">18</xref>]. This difference may be related to the long study period, systematic archival review, and detailed re-evaluation of surgical specimens, which likely improved detection sensitivity, particularly for rare histological variants and focal lesions.</p>
<p>The histological spectrum in our cohort was heterogeneous, comprising both benign and malignant entities. Squamous cell carcinoma (SCC) was the most frequent subtype, accounting for approximately one-third of cases, consistent with previous studies [<xref ref-type="bibr" rid="B18">18</xref>&#x2013;<xref ref-type="bibr" rid="B20">20</xref>]. This predominance is biologically plausible given the frequent squamous differentiation within mature teratomas. Rare entities, including paraganglioma, adult-type granulosa cell tumor, and central nervous system-type tumors, further highlight the broad differentiation potential and histological diversity of these lesions.</p>
<p>From a histogenetic perspective, mature teratomas (MTs) and adult granulosa cell tumors (AGCTs) arise from distinct embryological lineages [<xref ref-type="bibr" rid="B21">21</xref>]. Their coexistence in the same ovary is rare, with fewer than 15 cases reported [<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>] The most widely accepted explanation is the collision tumor theory, although alternative hypotheses, including divergent differentiation, have also been proposed [<xref ref-type="bibr" rid="B21">21</xref>]. Molecular studies, particularly FOXL2 mutation analysis, support the independent origin of AGCTs [<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>]. In our case, the synchronous presentation of AGCT and MT in the right ovary of a 50-year-old patient represents a rare entity. Morphologically, a 2.2&#xa0;cm solid area located within the wall of a 5&#xa0;cm&#xa0;MT exhibited classic AGCT features, characterized by uniform cells displaying microfollicular/insular patterns and nuclear grooves (coffee-bean nuclei); this diagnosis was confirmed by diffuse immunohistochemical positivity for inhibin and calretinin. Although molecular analysis for FOXL2 mutation could not be performed due to institutional limitations, the distinct histological demarcation between the two components, the absence of a transitional differentiation zone, and their entirely different embryological lineages rule out the possibility of a mixed/combined tumor. These findings strongly support that our case represents a pathological model of a &#x201c;collision tumor,&#x201d; characterized by the coincidental coexistence of two independent neoplasms.</p>
<p>The occurrence of glial neoplasms within mature cystic teratomas is exceptionally rare and is considered within the spectrum of monodermal teratomas. Although neuroectodermal differentiation is relatively common in mature teratomas, malignant transformation into high-grade astrocytic tumors is extremely uncommon. Clinically, these aggressive secondary malignancies typically affect young women, presenting primarily with non-specific abdominal pain and signs of mass effect [<xref ref-type="bibr" rid="B26">26</xref>]. From a diagnostic and macro-morphological perspective, evaluating these specimens carries inherent difficulties; because the astrocytic component arises directly within the background of an ovarian germ cell tumor framework, precisely measuring or isolating the exact boundaries and size of the astrocytoma can often be highly challenging [<xref ref-type="bibr" rid="B27">27</xref>]. This underscores the critical importance of extensive sampling and a comprehensive IHC panel to prevent diagnostic pitfalls. In our glioblastoma case, the diagnosis was supported by diffuse GFAP positivity, ATRX retention, p53 overexpression, a high Ki-67 proliferation index, and IDH1 (R132H) negativity, consistent with an IDH-wildtype phenotype. However, given the limited number of reported cases, the molecular profile of ovarian glioblastomas remains incompletely defined.</p>
<p>While some studies have suggested advanced age as a risk factor for somatic malignant transformation, others have failed to demonstrate it as an independent predictor [<xref ref-type="bibr" rid="B28">28</xref>]. In the present analysis, no significant differences were observed in age when assessed as a continuous variable or when stratified by a 45-year threshold. However, the broader age distribution observed in the SN-MT group indicates a need for more in-depth clinical and pathological evaluation of older patients.</p>
<p>Tumor size and macroscopic features appear to be important indicators of somatic neoplastic transformation [<xref ref-type="bibr" rid="B29">29</xref>]. In our study, SN-MTs were significantly larger and more frequently demonstrated mixed solid&#x2013;cystic architecture compared with MTs. The presence of solid areas, mural nodules, or necrosis should therefore raise suspicion for malignant transformation and prompt extensive sampling.</p>
<p>No statistically significant difference was observed between the MT and SN-MT groups in terms of tumor location. Although right-sided tumors were significantly more frequent in the SN-MT group, this finding should be interpreted with extreme caution due to the limited sample size of our cohort. This distribution reflects a random variation specific to small sample sizes rather than a clear biological mechanism. Similarly, the absence of somatic neoplasia in bilateral mature teratomas in our cohort should not be generalized and is likely due to the limited number of cases.</p>
<p>Serum tumor markers (CA 125, CA 19-9, and CEA) showed no significant difference between groups, consistent with previous reports indicating limited diagnostic value in predicting somatic transformation [<xref ref-type="bibr" rid="B30">30</xref>].</p>
<p>Although intraoperative frozen section analysis was performed in only a limited number of cases (n &#x3d; 7) in our cohort, our descriptive observations highlight the inherent diagnostic challenges associated with these lesions. In our small subset, the presence of focal and heterogeneous malignant components appeared to contribute to the difficulty of intraoperative assessment. While no definitive statistical conclusions can be drawn due to this sample size limitation, our experience suggests that careful procurement of samples, specifically targeting the solid components of the mass during intraoperative frozen section, may help minimize diagnostic pitfalls. Likewise, during gross evaluation of mature teratomas, meticulous and comprehensive sampling of heterogeneous areas remains a critical practice to facilitate the identification of potential SN-MT areas.</p>
<p>Malignant transformation was identified in eight patients, four of whom were diagnosed after TAH &#x2b; BSO and four after USO. The preference for more radical surgical approaches in SN-MT cases reflects the impact of suspicion of malignancy on surgical decision-making [<xref ref-type="bibr" rid="B31">31</xref>]. Despite the favourable outcomes observed in the majority of cases, particularly in patients with early-stage and completely resected tumors, advanced-stage patients demonstrated a need for chemotherapy.</p>
<p>Finally, several methodological limitations are acknowledged. The retrospective design inherently limits the data completeness and uniformity of measurements. An incomplete assessment of serum tumor markers may reduce the statistical power. The relatively small number of SN-MT cases constrained detailed subtype-specific analyses and generalizability. The lack of molecular and genetic investigations has limited mechanistic and prognostic interpretations. Nevertheless, the systematic pathological re-evaluation of all cases by expert pathologists, the long follow-up period, and the large overall cohort strengthened the significance of our findings. Future multicenter prospective studies incorporating molecular profiling are warranted to elucidate the biology of somatic neoplasms that arise in mature teratomas.</p>
<p>In conclusion, this study demonstrated that somatic neoplasms arising in mature teratomas represent a rare but highly heterogeneous clinicopathological entity. Larger tumor size and presence of solid components are the most reliable features associated with somatic neoplastic transformation. Our findings contribute to increased diagnostic awareness among pathologists and clinicians, and provide practical insights for the early recognition of this uncommon but clinically significant phenomenon. Further large-scale, multicenter, prospective studies are essential to validate these observations and facilitate the development of standardized diagnostic and therapeutic algorithms.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s5">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec sec-type="ethics-statement" id="s6">
<title>Ethics statement</title>
<p>The studies involving humans were approved by Antalya Training and Research Hospital Medical Research Scientific Ethics Board/Antalya Training and Research Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p>
</sec>
<sec sec-type="author-contributions" id="s7">
<title>Author contributions</title>
<p>&#x15e;Y: Conceptualization, Methodology, Investigation, Formal Analysis, Visualization, Writing &#x2013; original draft, Supervision, Project administration; GB: Conceptualization, Methodology, Investigation, Writing &#x2013; original draft, Supervision; DN: Methodology, Investigation, Formal Analysis, Visualization, Writing &#x2013; original draft; HY: Investigation, Formal Analysis; A&#xd6;: Data curation, Resources; I&#xdc;: Data curation, Resources. All authors contributed to the article and approved the submitted version.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>We would like to thank the Gynaecology and Obstetrics Clinic and the Pathology Clinic at Antalya Training and Research Hospital for their invaluable support.</p>
</ack>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of interest</title>
<p>The authors(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="s10">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>VW</given-names>
</name>
<name>
<surname>Ruiz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Killeen</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Cote</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>XC</given-names>
</name>
<name>
<surname>Correa</surname>
<given-names>CN</given-names>
</name>
<etal/>
</person-group> <article-title>Pathology and classification of ovarian tumors</article-title>. <source>Cancer Interdiscip Int J Am Cancer Soc</source> (<year>2003</year>) <volume>97</volume>(<issue>S10</issue>):<fpage>2631</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.11345</pub-id>
<pub-id pub-id-type="pmid">12733128</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<label>2.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ulbright</surname>
<given-names>TM</given-names>
</name>
</person-group>. <article-title>Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues</article-title>. <source>Mod Pathol</source> (<year>2005</year>) <volume>18</volume>:<fpage>S61</fpage>&#x2013;<lpage>S79</lpage>. <pub-id pub-id-type="doi">10.1038/modpathol.3800310</pub-id>
<pub-id pub-id-type="pmid">15761467</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<label>3.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pa&#x161;ali&#x107;</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Sabol</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Prtenja&#x10d;a</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Solomun</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Pavic</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Mature cystic teratoma and their malignant transformation</article-title>. <source>Eur J Surg Oncol</source> (<year>2025</year>) <volume>51</volume>(<issue>4</issue>):<fpage>109641</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejso.2025.109641</pub-id>
<pub-id pub-id-type="pmid">40348473</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<label>4.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jafari-Nozad</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Jahani</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nazeri</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Squamous cell carcinoma malignant transformation in mature cystic teratoma of the ovary: a case report and review of the literature</article-title>. <source>J Med Case Rep</source> (<year>2024</year>) <volume>18</volume>(<issue>1</issue>):<fpage>145</fpage>. <pub-id pub-id-type="doi">10.1186/s13256-024-04465-8</pub-id>
<pub-id pub-id-type="pmid">38523295</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<label>5.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kato</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kamataki</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kurotaki</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Methylation profiles of imprinted genes are distinct between mature ovarian teratoma, complete hydatidiform mole, and extragonadal mature teratoma</article-title>. <source>Mod Pathol</source> (<year>2021</year>) <volume>34</volume>(<issue>2</issue>):<fpage>502</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/s41379-020-00668-8</pub-id>
<pub-id pub-id-type="pmid">32873866</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<label>6.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>W-C</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>Y-C</given-names>
</name>
</person-group>. <article-title>DUSP5 and PHLDA1 mutations in mature cystic teratomas of the ovary identified on whole-exome sequencing may explain teratoma characteristics</article-title>. <source>Hum Genomics</source> (<year>2022</year>) <volume>16</volume>(<issue>1</issue>):<fpage>50</fpage>. <pub-id pub-id-type="doi">10.1186/s40246-022-00424-w</pub-id>
<pub-id pub-id-type="pmid">36289533</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<label>7.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Preoperative clinical characteristics for differentiating malignant transformation from torsion of mature cystic teratoma</article-title>. <source>J Obstet Gynaecol</source> (<year>2023</year>) <volume>43</volume>(<issue>1</issue>):<fpage>2151357</fpage>. <pub-id pub-id-type="doi">10.1080/01443615.2022.2151357</pub-id>
<pub-id pub-id-type="pmid">36519361</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<label>8.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emin</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Tayfun</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cantekin</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ba&#x15f;ak</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Umit</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Leyla</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Tumor markers in mature cystic teratomas of the ovary</article-title>. <source>Arch Gynecol Obstet</source> (<year>2009</year>) <volume>279</volume>(<issue>2</issue>):<fpage>145</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1007/s00404-008-0688-2</pub-id>
<pub-id pub-id-type="pmid">18506458</pub-id>
</mixed-citation>
</ref>
<ref id="B9">
<label>9.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tolaymat</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Yoshioka</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Feaster</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Costas</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bacaj</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zdilla</surname>
<given-names>MJ</given-names>
</name>
<etal/>
</person-group> <article-title>Retrospective analysis of a mature cystic teratoma discovered in the anatomy laboratory: cross-curricular integration of gross anatomy, histology, and embryology</article-title>. <source>Med Sci Educ</source> (<year>2025</year>) <volume>35</volume>(<issue>3</issue>):<fpage>1833</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s40670-025-02308-9</pub-id>
<pub-id pub-id-type="pmid">40625999</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<label>10.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Comerci</surname>
<given-names>JJT</given-names>
</name>
<name>
<surname>Licciardi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bergh</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Gregori</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Breen</surname>
<given-names>JL</given-names>
</name>
</person-group>. <article-title>Mature cystic teratoma: a clinicopathologic evaluation of 517 cases and review of the literature</article-title>. <source>Obstet Gynecol</source> (<year>1994</year>) <volume>84</volume>(<issue>1</issue>):<fpage>22</fpage>&#x2013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">8008317</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<label>11.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwasa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Oda</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kaneki</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ohishi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kurihara</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Squamous cell carcinoma arising in mature cystic teratoma of the ovary: an immunohistochemical analysis of its tumorigenesis</article-title>. <source>Histopathology</source> (<year>2007</year>) <volume>51</volume>(<issue>1</issue>):<fpage>98</fpage>&#x2013;<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2559.2007.02727.x</pub-id>
<pub-id pub-id-type="pmid">17542994</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<label>12.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Clinicopathological analysis of primary carcinoid tumour of the ovary arising in mature cystic teratomas</article-title>. <source>J Int Med Res</source> (<year>2021</year>) <volume>49</volume>(<issue>8</issue>):<fpage>03000605211034666</fpage>. <pub-id pub-id-type="doi">10.1177/03000605211034666</pub-id>
<pub-id pub-id-type="pmid">34459278</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<label>13.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leclerc</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tihy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Genestie</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hentic</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Koskas</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Updated morphological and immunohistochemical profile of neuroendocrine tumors developing in ovarian teratomas: a large series of a rare and heterogeneous disease</article-title>. <source>Int J Surg Pathol</source> (<year>2025</year>) <volume>33</volume>(<issue>3</issue>):<fpage>605</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1177/10668969241271923</pub-id>
<pub-id pub-id-type="pmid">39370906</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<label>14.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>XD</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>30-Year experience with 22 cases of malignant transformation arising from ovarian mature cystic teratoma: a rare disease</article-title>. <source>Front Oncol</source> (<year>2022</year>) <volume>12</volume>:<fpage>842703</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2022.842703</pub-id>
<pub-id pub-id-type="pmid">35615156</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<label>15.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saleh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bhosale</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Menias</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>Ramalingam</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Iyer</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>Ovarian teratomas: clinical features, imaging findings and management</article-title>. <source>Abdom Radiol</source> (<year>2021</year>) <volume>46</volume>(<issue>6</issue>):<fpage>2293</fpage>&#x2013;<lpage>307</lpage>. <pub-id pub-id-type="doi">10.1007/s00261-020-02873-0</pub-id>
<pub-id pub-id-type="pmid">33394097</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<label>16.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snir</surname>
<given-names>OL</given-names>
</name>
<name>
<surname>DeJoseph</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Buza</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hui</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Frequent homozygosity in both mature and immature ovarian teratomas: a shared genetic basis of tumorigenesis</article-title>. <source>Mod Pathol</source> (<year>2017</year>) <volume>30</volume>(<issue>10</issue>):<fpage>1467</fpage>&#x2013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1038/modpathol.2017.66</pub-id>
<pub-id pub-id-type="pmid">28664933</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<label>17.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marino</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Negri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Testa</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Corti</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Giuliani</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lugotti</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group> <article-title>Immature teratoma of the ovary&#x2014;A narrative review</article-title>. <source>Cancers</source> (<year>2025</year>) <volume>17</volume>(<issue>18</issue>):<fpage>3041</fpage>. <pub-id pub-id-type="doi">10.3390/cancers17183041</pub-id>
<pub-id pub-id-type="pmid">41008884</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<label>18.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neville</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Devins</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Nucci</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Watkins</surname>
<given-names>JC</given-names>
</name>
</person-group>. <article-title>Somatic malignancies arising in ovarian mature cystic teratomas: a multi-institutional study of 40 cases highlighting outcomes and novel malignancies</article-title>. <source>Am J Surg Pathol</source> (<year>2025</year>) <volume>49</volume>(<issue>6</issue>):<fpage>527</fpage>&#x2013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1097/PAS.0000000000002384</pub-id>
<pub-id pub-id-type="pmid">40070286</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<label>19.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Giannini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Girardo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Magrina</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Malignant transformation of squamous cell carcinoma in mature cystic teratoma of the ovary: a systematic review and meta-analysis of data</article-title>. <source>Gynecol Obstet Invest</source> (<year>2025</year>) <volume>90</volume>(<issue>3</issue>):<fpage>255</fpage>&#x2013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1159/000542672</pub-id>
<pub-id pub-id-type="pmid">39561732</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<label>20.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Squamous cell carcinoma arising from mature cystic teratoma of the ovary: a case report</article-title>. <source>SAGE Open Med Case Rep</source> (<year>2024</year>) <volume>12</volume>:<fpage>2050313X241272650</fpage>. <pub-id pub-id-type="doi">10.1177/2050313X241272650</pub-id>
<pub-id pub-id-type="pmid">39165301</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<label>21.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trivedi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Parikh</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Dave</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Granulosa cell tumor arising in an ovary with mature teratoma</article-title>. <source>Indian J Pathol Microbiol</source> (<year>2009</year>) <volume>52</volume>(<issue>4</issue>):<fpage>559</fpage>&#x2013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.4103/0377-4929.56166</pub-id>
<pub-id pub-id-type="pmid">19805973</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<label>22.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moid</surname>
<given-names>FY</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>RV</given-names>
</name>
</person-group>. <article-title>Granulosa cell tumor and mucinous cystadenoma arising in a mature cystic teratoma of the ovary: a unique case report and review of literature</article-title>. <source>Ann Diagn Pathol</source> (<year>2004</year>) <volume>8</volume>(<issue>2</issue>):<fpage>96</fpage>&#x2013;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1053/j.anndiagpath.2004.01.007</pub-id>
<pub-id pub-id-type="pmid">15060888</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<label>23.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aljehani</surname>
<given-names>AM</given-names>
</name>
</person-group>. <article-title>Unilateral adult type granulosa cell tumor in patient with bilateral mature cystic teratoma treated with fertility-preserving surgery: a case report</article-title>. <source>J Pioneering Med Sci</source> (<year>2025</year>) <volume>14</volume>(<issue>7</issue>):<fpage>16</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.47310/jpms2025140704</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<label>24.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Adult-type granulosa cell tumor of the ovary</article-title>. <source>Am J Cancer Res</source> (<year>2022</year>) <volume>12</volume>(<issue>8</issue>):<fpage>3495</fpage>&#x2013;<lpage>511</lpage>.<pub-id pub-id-type="pmid">36119817</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<label>25.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>&#x160;afanda</surname>
<given-names>A</given-names>
</name>
<name>
<surname>H&#xe1;jkov&#xe1;</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Galko</surname>
<given-names>J</given-names>
</name>
<name>
<surname>B&#xe1;rt&#x16f;</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Dundr</surname>
<given-names>P</given-names>
</name>
<name>
<surname>N&#x11b;mejcov&#xe1;</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>An unusual case of late recurrent adult granulosa cell tumor and mature teratoma arising within the same ovary, confirmed by NGS analysis</article-title>. <source>Cesk Patol</source> (<year>2025</year>) <volume>61</volume>(<issue>4</issue>):<fpage>205</fpage>&#x2013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">41689791</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<label>26.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bussies</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Chau</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Hunt</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Policarpio-Nicolas</surname>
<given-names>MLC</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>McKenney</surname>
<given-names>JK</given-names>
</name>
<etal/>
</person-group> <article-title>Secondary somatic glioblastoma arising from a mature ovarian cystic teratoma in a patient with underlying Li-Fraumeni syndrome</article-title>. <source>Gynecol Oncol Rep</source> (<year>2023</year>) <volume>49</volume>(<issue>26</issue>):<fpage>101279</fpage>. <pub-id pub-id-type="doi">10.1016/j.gore.2023.101279</pub-id>
<pub-id pub-id-type="pmid">37840845</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<label>27.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Olar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Bian</surname>
<given-names>XW</given-names>
</name>
<etal/>
</person-group> <article-title>Primary glial and neuronal tumors of the ovary or peritoneum: a clinicopathologic study of 11 cases</article-title>. <source>Am J Surg Pathol</source> (<year>2016</year>) <volume>40</volume>(<issue>6</issue>):<fpage>847</fpage>&#x2013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1097/PAS.0000000000000635</pub-id>
<pub-id pub-id-type="pmid">26990854</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<label>28.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cong</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yeung</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JHS</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>JPW</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>DYL</given-names>
</name>
</person-group>. <article-title>Mature cystic teratoma: an integrated review</article-title>. <source>Int J Mol Sci</source> (<year>2023</year>) <volume>24</volume>(<issue>7</issue>):<fpage>6141</fpage>. <pub-id pub-id-type="doi">10.3390/ijms24076141</pub-id>
<pub-id pub-id-type="pmid">37047114</pub-id>
</mixed-citation>
</ref>
<ref id="B29">
<label>29.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawaguchi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Furui</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Noda</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hyodo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Miyazaki</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>MRI findings of malignant transformation arising from mature cystic teratoma of the ovary: comparison with benign mature cystic teratoma</article-title>. <source>Jpn J Radiol</source> (<year>2024</year>) <volume>42</volume>(<issue>5</issue>):<fpage>500</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1007/s11604-023-01521-z</pub-id>
<pub-id pub-id-type="pmid">38146022</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<label>30.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Malignant transformation of ovarian mature cystic teratoma with rupture, elevated serum CA199, CA12, CEA: a case report</article-title>. <source>Medicine</source> (<year>2024</year>) <volume>103</volume>(<issue>37</issue>):<fpage>e38793</fpage>. <pub-id pub-id-type="doi">10.1097/MD.0000000000038793</pub-id>
<pub-id pub-id-type="pmid">39287252</pub-id>
</mixed-citation>
</ref>
<ref id="B31">
<label>31.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atwi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kamal</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Quinton</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hassell</surname>
<given-names>LA</given-names>
</name>
</person-group>. <article-title>Malignant transformation of mature cystic teratoma of the ovary</article-title>. <source>J Obstet Gynaecol Res</source> (<year>2022</year>) <volume>48</volume>(<issue>12</issue>):<fpage>3068</fpage>&#x2013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1111/jog.15409</pub-id>
<pub-id pub-id-type="pmid">36053141</pub-id>
</mixed-citation>
</ref>
</ref-list>
<fn-group>
<fn fn-type="custom" custom-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1099044/overview">Natalia Buza</ext-link>, Yale University, United States</p>
</fn>
</fn-group>
</back>
</article>